Our bioinformatics analyses showed that CRC patients with high-GRAF1 had better overall survival (OS) than patients with low-GRAF1 but not progression-free survival (PFS) (Supplementary Fig. S1C), while CRC patients with high-CEMIP had shorter PFS than patients with low-CEMIP but not OS (Supplementary Fig. S1D). This evidence concerns the gene ARHGAP26 and colorectal carcinoma.